Lebanese Interhospital Pneumococcal Surveillance Program (LIPSP)

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Streptococcus pneumoniae (pneumococcus) is a bacterium that causes severe infections in children and adults such as meningitis, pneumonia, and blood stream infection. There are many types of these bacteria defined by the type of sugar coat that they have. These are classified as serotypes. There are common serotypes that cause severe disease and are preventable by vaccination of children. Other less common types are more difficult to prevent. The investigators aim to determine the serotypes that cause invasive pneumococcal disease in Lebanon and to study their sensitivity to different antibiotics. The investigators will collect bacterial isolates from different hospitals in Lebanon isolated from the blood or spinal fluid of patients with invasive pneumococcal disease. This information will help the investigators determine the usefulness of available pneumococcal vaccines in preventing these infections. The data will be distributed to all primary care physicians treating children in Lebanon and will be shared with the Ministry of Health.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 1 day
Healthy Volunteers: f
View:

• Samples included in the study are those that are:

‣ culture proven

⁃ invasive pneumococcal infections

⁃ in patients of all ages admitted to different hospitals all over Lebanon

• Acceptable samples include:

‣ positive isolates from blood

⁃ cerebrospinal fluid

⁃ other normally sterile body sites such as empyema fluid, abscesses, joint fluid, middle ear fluid obtained by tympanocentesis in the operating room, and lung needle aspiration

Locations
Other Locations
Lebanon
American University of Beirut
RECRUITING
Beirut
Contact Information
Primary
Ghassan S Dbaibo, M.D.
gdbaibo@aub.edu.lb
+961-1-749235
Backup
Mireille Lteif, RN
ml12@aub.edu.lb
+961-1-350000
Time Frame
Start Date: 2005-10
Estimated Completion Date: 2030-10
Participants
Target number of participants: 700
Related Therapeutic Areas
Sponsors
Collaborators: Pfizer, PneumoADIP
Leads: American University of Beirut Medical Center

This content was sourced from clinicaltrials.gov